Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-08 00:30 | 2026-01-05 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $487.38 | 7,875 | $3,838,085 | 0 |
| 2026-01-07 00:00 | 2026-01-05 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,085.01 | 1,390 | $1,508,165 | 92,189,126 |
| 2026-01-07 00:16 | 2026-01-05 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Officer | SELL | $10.44 | 4,170 | $43,543 | 160,222 |
| 2026-01-07 01:25 | 2025-05-22 | IBO | IMPACT BIOMEDICAL INC. | DSS, INC. | 10% owner | SELL | $0.55 | 161,000 | $88,003 | 545,024 |
| 2026-01-07 04:25 | 2026-01-02 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Officer | SELL | $38.57 | 1,155 | $44,553 | 50,365 |
| 2026-01-07 04:26 | 2026-01-05 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | Director, Officer | OPT+S | $38.10 | 71,339 | $2,718,230 | 138,976 |
| 2026-01-07 00:02 | 2025-12-24 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | Officer | SELL | $35.80 | 2,072 | $74,181 | 7,141 |
| 2026-01-07 00:17 | 2026-01-02 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $38.48 | 20,000 | $769,650 | 80,000 |
| 2026-01-07 00:18 | 2026-01-02 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $38.42 | 69,582 | $2,673,041 | 39,760 |
| 2026-01-07 00:30 | 2026-01-02 | GLTO | Galecto, Inc. | Schambye Hans T. | Director, Officer | OPT+S | $21.38 | 700 | $14,966 | 4,682 |
| 2026-01-07 00:30 | 2026-01-02 | GLTO | Galecto, Inc. | Winslow Garrett | Officer | OPT+S | $21.38 | 255 | $5,452 | 1,854 |
| 2026-01-07 00:30 | 2026-01-02 | GLTO | Galecto, Inc. | Firmani Lori | Officer | OPT+S | $21.41 | 135 | $2,890 | 931 |
| 2026-01-07 01:35 | 2026-01-02 | IONS | IONIS PHARMACEUTICALS INC | Swayze Eric | Officer | OPT+S | $79.12 | 23,463 | $1,856,325 | 30,453 |
| 2026-01-07 01:31 | 2026-01-02 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | SELL | $28.96 | 10,000 | $289,606 | 69,744 |
| 2026-01-07 04:00 | 2026-01-02 | BCYC | BICYCLE THERAPEUTICS PLC | Hannay Michael Charles Ferguson | Officer | SELL | $6.64 | 5,194 | $34,491 | 97,908 |
| 2026-01-07 04:00 | 2026-01-02 | BCYC | BICYCLE THERAPEUTICS PLC | Thompson Travis Alvin | Officer | SELL | $6.64 | 2,432 | $16,147 | 66,265 |
| 2026-01-07 04:00 | 2026-01-02 | BCYC | BICYCLE THERAPEUTICS PLC | Young Alethia | Officer | SELL | $6.62 | 7,623 | $50,489 | 87,081 |
| 2026-01-07 04:00 | 2026-01-02 | BCYC | BICYCLE THERAPEUTICS PLC | Milnes Alistair | Officer | SELL | $6.63 | 6,660 | $44,126 | 136,717 |
| 2026-01-07 04:00 | 2026-01-02 | BCYC | BICYCLE THERAPEUTICS PLC | Lee Kevin | Director, Officer | SELL | $6.62 | 21,314 | $141,199 | 618,996 |
| 2026-01-07 04:00 | 2026-01-02 | BCYC | BICYCLE THERAPEUTICS PLC | Skynner Michael | Officer | SELL | $6.62 | 6,311 | $41,804 | 161,966 |
| 2026-01-07 03:20 | 2026-01-02 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $35.25 | 262,752 | $9,261,036 | 61,804 |
| 2026-01-07 05:36 | 2026-01-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $30.68 | 15,000 | $460,134 | 671,907 |
| 2026-01-07 05:30 | 2026-01-02 | WVE | Wave Life Sciences Ltd. | Francis Chris | Officer | OPT+S | $16.03 | 9,375 | $150,260 | 25,000 |
| 2026-01-07 00:05 | 2026-01-02 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $42.00 | 2,592 | $108,858 | 447,331 |
| 2026-01-07 00:30 | 2026-01-02 | FULC | Fulcrum Therapeutics, Inc. | Gould Robert J | Director | SELL | $11.87 | 15,000 | $178,089 | 469,864 |
| 2026-01-07 02:14 | 2026-01-05 | XERS | Xeris Biopharma Holdings, Inc. | Shannon John Patrick Jr | Director, Officer | OPT+S | $7.08 | 24,907 | $176,257 | 2,705,346 |
| 2026-01-07 00:06 | 2026-01-05 | APLS | Apellis Pharmaceuticals Inc. | Baumal Caroline | Officer | SELL | $25.53 | 3,020 | $77,097 | 91,206 |
| 2026-01-07 01:30 | 2026-01-05 | PCRX | Pacira BioSciences, Inc. | RIKER LAUREN | Officer | SELL | $24.24 | 1,416 | $34,324 | 59,064 |
| 2026-01-07 05:04 | 2026-01-05 | ANAB | AnaptysBio Inc. | Lizzul Paul F. | Officer | OPT+S | $43.26 | 4,219 | $182,514 | 33,303 |
| 2026-01-07 05:07 | 2026-01-05 | ANAB | AnaptysBio Inc. | Faga Daniel | Director, Officer | OPT+S | $43.26 | 15,309 | $662,267 | 458,139 |
| 2026-01-07 00:05 | 2026-01-02 | RCKT | ROCKET PHARMACEUTICALS, INC. | Bjork Elisabeth | Director | BUY | $3.44 | 10,000 | $34,400 | 50,000 |
| 2026-01-07 05:05 | 2026-01-05 | ANAB | AnaptysBio Inc. | MULROY DENNIS | Officer | OPT+S | $43.26 | 3,363 | $145,483 | 14,330 |
| 2026-01-07 05:03 | 2026-01-05 | ANAB | AnaptysBio Inc. | LOUMEAU ERIC J | Officer | OPT+S | $43.26 | 2,983 | $129,045 | 13,251 |
| 2026-01-07 03:47 | 2026-01-02 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $189.58 | 467 | $88,533 | 43,654 |
| 2026-01-07 00:24 | 2026-01-02 | BIOA | BioAge Labs, Inc. | RUBIN PAUL D | Officer | OPT+S | $12.85 | 7,433 | $95,490 | 0 |
| 2026-01-07 00:54 | 2026-01-02 | GALT | GALECTIN THERAPEUTICS INC | LEWIS JOEL | Director, Officer | OPT+S | $3.82 | 84,000 | $321,132 | 832,592 |
| 2026-01-07 00:54 | 2026-01-02 | GALT | GALECTIN THERAPEUTICS INC | CALLICUTT JACK W | Officer | OPT+S | $3.89 | 60,000 | $233,388 | 7,614 |
| 2026-01-07 00:53 | 2026-01-02 | GALT | GALECTIN THERAPEUTICS INC | Jamil Khurram | Officer | OPT+S | $3.87 | 60,000 | $232,404 | 0 |
| 2026-01-07 00:06 | 2026-01-05 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | OPT+S | $171.38 | 12,303 | $2,108,507 | 94,754 |
| 2026-01-07 00:03 | 2026-01-02 | INSM | INSMED Inc | Schaeffer Orlov S Nicole | Officer | OPT+S | $175.20 | 87,290 | $15,293,417 | 41,754 |
| 2026-01-07 00:31 | 2026-01-05 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | SELL | $495.01 | 50 | $24,751 | 370 |
| 2026-01-07 00:31 | 2026-01-06 | UTHR | UNITED THERAPEUTICS Corp | CAUSEY CHRISTOPHER | Director | OPT+S | $510.00 | 1,000 | $510,000 | 4,190 |
| 2026-01-07 01:20 | 2026-01-05 | PTCT | PTC THERAPEUTICS, INC. | Reeve Emma | Director | OPT+S | $76.00 | 734 | $55,784 | 10,666 |
| 2026-01-07 01:20 | 2026-01-05 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $75.55 | 2,266 | $171,192 | 120,901 |
| 2026-01-07 01:20 | 2026-01-02 | PTCT | PTC THERAPEUTICS, INC. | STEELE GLENN JR MD PHD | Director | OPT+S | $76.35 | 12,000 | $916,200 | 18,500 |
| 2026-01-06 00:20 | 2025-12-31 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $30.05 | 6,567 | $197,338 | 404,075 |
| 2026-01-06 00:19 | 2025-12-31 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Officer | SELL | $30.05 | 2,840 | $85,342 | 296,991 |
| 2026-01-06 04:18 | 2026-01-05 | ZYME | Zymeworks Inc. | Moore Paul Andrew | Officer | OPT+S | $25.10 | 20,110 | $504,699 | 40,391 |
| 2026-01-06 00:30 | 2026-01-02 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $100.51 | 10,000 | $1,005,114 | 49,086 |
| 2026-01-06 00:30 | 2026-01-02 | XLO | Xilio Therapeutics, Inc. | Brennan Kevin M. | Officer | OPT+S | $0.64 | 1,826 | $1,174 | 6,371 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.